EU Reverses Stance, Supports Lecanemab for Early Alzheimer's Treatment
The European Medicines Agency has approved Lecanemab, a drug targeting the cause of Alzheimer's disease, marking a potential turning point in its treatment. Developed by BioArctic and Eisai, Lecanemab aims to delay Alzheimer's progression by removing beta-amyloid plaques in the brain. While it offers hope, the drug's benefits are limited, delaying symptoms by about five months, and it poses risks like brain hemorrhages. The approval highlights the ongoing challenges and potential of antibody therapies in Alzheimer's treatment, with further research and infrastructure needed for widespread application.